The Women's Screening and Self-Testing Program (PROMETA) Study

Arms (1)

1. type

   EXPERIMENTAL

   label

   HPV DNA testing from self-collected vaginal swab

   description

   After providing informed consent, the study clinician will open a Case Report Form (CRF) for each patient which starts with a brief questionnaire which will include the participant's demographic information and medical history, including HIV viral load and CD4 counts, previous cervical cancer screening results if previously screened, and result of rapid pregnancy test performed that day with a urine sample. Each participant will then be accompanied to a private location where the study nurse will provide counseling and instruction on how to appropriately perform the self-collection vaginal swab technique. Data on HPV testing, VAT results, and referrals along each step of the process will be documented in the CRF.

   interventionNames

   1. Diagnostic Test: HPV DNA testing be self-collected vaginal swab

Primary outcomes (1)

1. measure

   The number of women screened and the proportion of screen-positive women successfully undergoing treatment or evaluation/referral.

   timeFrame

   2.5 Years

   description

   Baseline data will be retrospectively collected for the prior 12 months at each of the selected study sites, including the number of women accessing care for HIV care and treatment services each month; the number of women screened for cervical cancer through standard of care protocols; the proportion of screen-positive women who then received treatment or referral for treatment, and the length of time between screening positive and receiving treatment if appropriate.